AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

GileadSciences.Shutterstock

News

Intraday Update

Markets

Movers

Trading Ideas

ANAB

ANGI

CFLT

CHEF

CLMT

CRSP

GILD

UPST

VNET

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday

Upstart Holdings, Inc. UPST

APGE

ATOM

KDLY

LYFT

MYNA

OMGA

SMWB

SOPA

SPIR

STAA

WINT

Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Recent Gains

Pre-Market Outlook

DOGZ

GHRS

IRON

PRGS

SEPN

ZBIO

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

AnaptysBio Inc

Press Releases

Anaptys Announces Participation in November and December Investor Conferences

Health Care

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

General

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Earnings

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Anaptys Announces Participation in March Investor Conferences

VNDA

Abivax

Altimmune

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Chimerix

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Relay Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sana Biotechnology

Sionna Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tyra Biosciences

Valneva

Verve Therapeutics

Wells Fargo

Wedbush

HC Wainwright & Co.

JP Morgan

Truist Securities

Comments

AnaptysBio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga